T. Jenkins, and A.G. Sturmer
Elysium Therapeutics, Inc., Ohio, United States
Poster stand number: W123
Keywords: fentanyl, overdose, WMD, synthetic opioid, countermeasureThe very high potency, ease of synthesis, and widespread availability of long-acting synthetic opioids (e.g., fentanyl, carfentanil) pose a significant public health risk not only to civilians with substance use disorders, but also to law enforcement personnel, first responders, and the military because these chemicals are easily weaponized, which could lead to mass casualties. Current rescue agents (e.g., Narcan®) were not designed with the potency of synthetic opioids in mind, and they fall short. To be effective, it often requires multiple doses of these agents. The lethal effect of synthetic opioids on breathing lasts significantly longer than other opioids, causing severe brain injury or death even after administering existing rescue agents. Given existing rescue agents shortcomings against individual synthetic opioid overdose, they would have limited value in a mass casualty event. Thus, there is a need for a potent, long-acting antidote for individual and mass casualty synthetic opioid agonist poisoning. We present data on our common solution, ETR201 – a novel, easily administered, fast-onset, long-acting nalmefene prodrug as an effective countermeasure to synthetic opioids for overdose victims, military personnel, law enforcement, and first-responders.